Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib + Ralimetinib in Advanced Cancer
NCT02860780Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of prexasertib in cancer, metastatic cancer, colorectal cancer (CRC) and 1 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose of Prexasertib and Ralimetinib. Started Aug 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
cancermetastatic cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02860780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860780.